ROKIT Healthcare has released long-term real-world evidence (RWE) from its AI-driven 3D bioprinting regenerative medicine platform, showing a 94.9% wound healing rate within 12 weeks across global clinical sites. The data, spanning three years, underscores the platform's commercial viability and potential cost savings for clinics and distributors in the chronic wound care segment.
Real-world evidence highlights
According to the company's 'Skin & Wound RWE White Paper,' 94.9% of patients with hard-to-heal chronic wounds achieved closure within 12 weeks of treatment, with an average healing time of 7.7 weeks. No amputations were reported among diabetic foot ulcer patients during the follow-up period. The analysis is based on real clinical data from multiple countries, not a controlled trial, strengthening the case for broader adoption.
Cost-effectiveness for buyers
A cost-effectiveness analysis aligned with UK NICE criteria found that the AI skin regeneration platform reduces medical costs by approximately 60% compared to conventional skin grafts and by about 20% versus negative pressure wound therapy (NPWT). For distributors and clinic buyers, this suggests a strong value proposition for payers and healthcare institutions seeking to lower treatment expenses while improving outcomes.
Global case examples
Clinical cases from partner institutions were cited: a diabetic foot patient at Nishitokushukai Hospital in Tokyo healed in 5 weeks; a patient at the Virginia Vascular Institute in the US recovered in 8 weeks; a severe wound case at the Egyptian Air Force Specialist Hospital healed in 5 weeks; and a severe burn patient in Turkey achieved skin regeneration in 9 weeks. The company noted consistent results across countries, ethnicities, and wound types.
What buyers should watch
ROKIT Healthcare's platform uses a small amount of autologous tissue to create patient-specific regenerative patches, avoiding the need for harvesting healthy skin. The absence of amputations in the study period is a key differentiator for diabetic foot care. For importers and distributors, this RWE data could support regulatory submissions and reimbursement negotiations in new markets. The company aims to expand globally and position its technology as a new standard in chronic wound management.
Source: Read the original report | Published: June 10, 2026